InvestorsObserver
×
News Home

How Will the Market React to AbCellera Biologics Inc (ABCL) Stock Getting a Bearish Rating

Friday, March 10, 2023 02:14 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to AbCellera Biologics Inc (ABCL) Stock Getting a Bearish Rating

AbCellera Biologics Inc (ABCL) stock is lower by 11.69% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
AbCellera Biologics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ABCL!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ABCL Stock Today?

AbCellera Biologics Inc (ABCL) stock is trading at $7.40 as of 2:14 PM on Friday, Mar 10, a loss of -$0.47, or -5.95% from the previous closing price of $7.87. The stock has traded between $7.33 and $7.94 so far today. Volume today is 1,818,916 compared to average volume of 1,755,238.

More About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. The Company operates in single segment, discovery and development of antibodies. The company's revenue is comprised of partnership research fees, licensing revenue, development milestones, and royalty payments from commercial products. Click Here to get the full Stock Report for AbCellera Biologics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App